{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:09:43Z","timestamp":1789153783874,"version":"build-2803163510"},"reference-count":50,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["aao-hnsfjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Otolaryngol.--head neck surg."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of pharmacologic therapies for spontaneous epistaxis in hereditary hemorrhagic telangiectasia (HHT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>PubMed, Scopus, Embase, Web of Science, and the Cochrane Library were systematically searched up to August 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Review Methods<\/jats:title>\n                    <jats:p>Eligible randomized controlled trials evaluating bevacizumab, doxycycline, tranexamic acid, or \u03b2\u2010blockers versus placebo or standard care were included. Outcomes included epistaxis frequency and duration, hemoglobin (Hb), epistaxis severity score (ESS), transfusion or emergent\u2010care requirements, quality of life (QOL), and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Tranexamic acid did not significantly reduce epistaxis duration or frequency or improve Hb, and it did not change transfusion or emergent\u2010care needs, but it increased diarrhea (odds ratio 3.8, 95% confidence interval [CI] [1.7; 8.5]). Bevacizumab produced a modest reduction in epistaxis frequency (standardized mean difference \u22120.25, 95% CI [\u22120.47; \u22120.02]), without significant effects on duration, ESS, Hb, or QOL. Doxycycline showed no significant benefit for duration or frequency. Topical or systemic \u03b2\u2010blockers did not significantly affect ESS, QOL, Hb, or overall adverse events. Across agents, between\u2010study heterogeneity was generally low to moderate and CIs were wide, reflecting limited sample sizes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>No pharmacologic agent demonstrated consistent, clinically robust superiority over placebo across primary endpoints. Bevacizumab may modestly reduce bleeding burden, whereas tranexamic acid increases gastrointestinal toxicity without clear efficacy. Pharmacologic control of HHT\u2010related epistaxis remains suboptimal, underscoring the need for adequately powered trials with standardized outcome measures and optimized dosing and delivery strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ohn.70428","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:44:35Z","timestamp":1789152275000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Various Medications in the Treatment of Hereditary Hemorrhagic Telangiectasia Epistaxis"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7677-4219","authenticated-orcid":false,"given":"Yun Jin","family":"Kang","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Yeouido St. Mary's Hospital, College of Medicine The Catholic University of Korea Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Su","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Yeouido St. Mary's Hospital, College of Medicine The Catholic University of Korea Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulnaz","family":"Stybayeva","sequence":"additional","affiliation":[{"name":"Department of Physiology and Biomedical Engineering Mayo Clinic Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2838-7820","authenticated-orcid":false,"given":"Se Hwan","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Bucheon St. Mary's Hospital, College of Medicine The Catholic University of Korea Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4193\/Rhino14.274","article-title":"Hereditary haemorrhagic telangiectasia","volume":"53","author":"Rimmer J","year":"2015","journal-title":"Rhinol J"},{"key":"e_1_2_10_3_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-024-00585-z","article-title":"Hereditary haemorrhagic telangiectasia","volume":"11","author":"Hermann R","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"e_1_2_10_4_1","volume-title":"Hereditary Hemorrhagic Telangiectasia","author":"McDonald J.","year":"2000"},{"key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/alr.23566","article-title":"The effect of systemic bevacizumab on epistaxis\u2010related outcomes in hereditary hemorrhagic telangiectasia: a systematic review and meta\u2010analysis","volume":"15","author":"Li W","year":"2025","journal-title":"Int Forum Allergy Rhinol"},{"key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12955-017-0586-z","article-title":"Quality of life in patients with hereditary haemorrhagic telangiectasia (HHT)","volume":"15","author":"Zarrabeitia R","year":"2017","journal-title":"Health Qual Life Outcomes"},{"key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/alr.21374","article-title":"The effects of epistaxis on health\u2010related quality of life in patients with hereditary hemorrhagic telangiectasia","volume":"4","author":"Merlo CA","year":"2014","journal-title":"Int Forum Allergy Rhinol"},{"key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/M20-1443","article-title":"Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia","volume":"173","author":"Faughnan ME","year":"2020","journal-title":"Ann Intern Med"},{"key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/jth.12654","article-title":"Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross\u2010over controlled trial in a rare disease","volume":"12","author":"Gaillard S","year":"2014","journal-title":"J Thromb Haemostasis"},{"key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.thromres.2014.06.012","article-title":"Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid\u2014a double\u2010blind placebo\u2010controlled cross\u2010over phase IIIB study","volume":"134","author":"Geisthoff UW","year":"2014","journal-title":"Thromb Res"},{"key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/00034894221078075","article-title":"Sclerotherapy for hereditary hemorrhagic telangiectasia\u2010related epistaxis: a systematic review","volume":"132","author":"Thiele B","year":"2023","journal-title":"Ann Otol, Rhinol, Laryngol"},{"key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/lsm.23147","article-title":"Laser\u2010assisted control of epistaxis in hereditary hemorrhagic telangiectasia: a systematic review","volume":"52","author":"Abiri A","year":"2020","journal-title":"Lasers Surg Med"},{"key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4193\/Rhin16.315","article-title":"Nasal closure for severe hereditary haemorrhagic telangiectasia in 100 patients. The Lund modification of the Young's procedure: a 22\u2010year experience","volume":"55","author":"Lund VJ","year":"2017","journal-title":"Rhinol J"},{"key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/jmg.2009.069013","article-title":"International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia","volume":"48","author":"Faughnan ME","year":"2011","journal-title":"J Med Genet"},{"key":"e_1_2_10_15_1","first-page":"15","article-title":"Angiogenesis in hereditary hemorrhagic telangiectasia: VEGF165 plasma concentration in correlation to the VEGF expression and microvessel density","volume":"15","author":"Sadick H","year":"2005","journal-title":"Int J Mol Med"},{"key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000072411","article-title":"Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia","volume":"110","author":"Cirulli A","year":"2003","journal-title":"Acta Haematol"},{"key":"e_1_2_10_17_1","first-page":"818","article-title":"Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor\u2010beta1 as well as high ALK1 tissue expression","volume":"90","author":"Sadick H","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_10_18_1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/joim.12832","article-title":"Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia","volume":"285","author":"Al\u2010Samkari H","year":"2019","journal-title":"J Intern Med"},{"key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/0194599818797316","article-title":"Medical treatment for epistaxis in hereditary hemorrhagic telangiectasia: a meta\u2010analysis","volume":"160","author":"Hsu YP","year":"2019","journal-title":"Otolaryngol Head Neck Surg"},{"key":"e_1_2_10_20_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4193\/Rhin17.166","article-title":"Intranasal bevacizumab in the treatment of HHT\u2010related epistaxis: a systematic review","volume":"56","author":"Stokes P","year":"2018","journal-title":"Rhinol J"},{"key":"e_1_2_10_21_1","doi-asserted-by":"crossref","first-page":"E313","DOI":"10.1002\/ajh.24367","article-title":"Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding","volume":"91","author":"Epperla N","year":"2016","journal-title":"Am J Hematol"},{"key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2017.11.013","article-title":"Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia\u2010related epistaxis and gastrointestinal bleeding","volume":"93","author":"Iyer VN","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_10_23_1","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.2012.250","article-title":"Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output","volume":"307","author":"Dupuis\u2010Girod S","year":"2012","journal-title":"JAMA"},{"key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s00405-024-09177-9","article-title":"Efficacy of bevacizumab in hereditary hemorrhagic telangiectasia: a systematic review and network meta\u2010analysis","volume":"282","author":"Taha AM","year":"2025","journal-title":"Eur Arch Otrhinolaryngol"},{"key":"e_1_2_10_25_1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11882-023-01116-8","article-title":"Treatments of epistaxis in hereditary hemorrhagic telangiectasia: systematic review and network meta\u2010analysis","volume":"23","author":"Chitsuthipakorn W","year":"2023","journal-title":"Curr Allergy Asthma Rep"},{"key":"e_1_2_10_26_1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.4161\/mabs.28025","article-title":"ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia","volume":"6","author":"Dupuis\u2010Girod S","year":"2014","journal-title":"Mabs"},{"key":"e_1_2_10_27_1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/s13023-022-02539-8","article-title":"Randomized, double\u2010blind, placebo\u2010controlled, crossover trial of oral doxycycline for epistaxis in hereditary hemorrhagic telangiectasia","volume":"17","author":"Thompson KP","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"e_1_2_10_28_1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/hed.23655","article-title":"Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double\u2010blind, randomized, placebo\u2010controlled trial","volume":"37","author":"Riss D","year":"2015","journal-title":"Head Neck"},{"key":"e_1_2_10_29_1","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jama.2016.11387","article-title":"Effect of bevacizumab nasal spray on epistaxis duration in hereditary hemorrhagic telangectasia: a randomized clinical trial","volume":"316","author":"Dupuis\u2010Girod S","year":"2016","journal-title":"JAMA"},{"key":"e_1_2_10_30_1","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.2016.11724","article-title":"Effect of topical intranasal therapy on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia: a randomized clinical trial","volume":"316","author":"Whitehead KJ","year":"2016","journal-title":"JAMA"},{"key":"e_1_2_10_31_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48502-9","article-title":"Efficacy of TIMOLOL nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia. A double\u2010blind, randomized, placebo\u2010controlled trial","volume":"9","author":"Dupuis\u2010Girod S","year":"2019","journal-title":"Sci Rep"},{"key":"e_1_2_10_32_1","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.3390\/jcm9103130","article-title":"Topical propranolol improves epistaxis control in hereditary hemorrhagic telangiectasia (HHT): a randomized double\u2010blind placebo\u2010controlled trial","volume":"9","author":"Mei\u2010Zahav M","year":"2020","journal-title":"J Clin Med"},{"key":"e_1_2_10_33_1","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jamaoto.2020.3025","article-title":"Efficacy of timolol in a novel intranasal thermosensitive gel for hereditary hemorrhagic telangiectasia\u2010associated epistaxis: a randomized clinical trial","volume":"146","author":"Peterson AM","year":"2020","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"e_1_2_10_34_1","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/alr.22961","article-title":"Randomized, controlled, double\u2010blinded clinical trial of effect of bevacizumab injection in management of epistaxis in hereditary hemorrhagic telangiectasia patients undergoing surgical cauterization","volume":"12","author":"Khanwalkar AR","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"e_1_2_10_35_1","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/jth.15662","article-title":"North American study for the treatment of recurrent epistaxis with doxycycline: the NOSTRIL trial","volume":"20","author":"McWilliams JP","year":"2022","journal-title":"J Thromb Haemostasis"},{"key":"e_1_2_10_36_1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/CH-211253","article-title":"TIMolol nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia (HHT) \u2010 Study protocol of the prospective, randomized, double\u2010blind, controlled cross\u2010over TIM\u2010HHT trial","volume":"80","author":"Andorfer KEC","year":"2022","journal-title":"Clin Hemorheol Microcirc"},{"key":"e_1_2_10_37_1","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/joim.13714","article-title":"Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: a national, randomized multicenter trial","volume":"294","author":"Dupuis\u2010Girod S","year":"2023","journal-title":"J Intern Med"},{"issue":"4","key":"e_1_2_10_38_1","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ohn.1339","article-title":"Short\u2010term efficacy of biologics in recalcitrant allergic fungal rhinosinusitis: a systematic review and meta\u2010analysis","volume":"173","author":"Im YH","year":"2025","journal-title":"Otolaryngol Head Neck Surg"},{"key":"e_1_2_10_39_1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/ohn.1057","article-title":"Dose\u2010related effects and bleeding risk of ketorolac in pediatric tonsillectomy","volume":"172","author":"Kim DH","year":"2025","journal-title":"Otolaryngol Head Neck Surg"},{"key":"e_1_2_10_40_1","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3324\/haematol.2020.261859","article-title":"An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT\u2010Bleed study","volume":"106","author":"Hanny al\u2010Samkari A","year":"2021","journal-title":"Haematologica"},{"key":"e_1_2_10_41_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2500\/ar.2014.5.0091","article-title":"Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia","volume":"5","author":"Thompson AB","year":"2014","journal-title":"Allergy Rhinol (Providence)"},{"key":"e_1_2_10_42_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188943","article-title":"Intra\u2010venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): a retrospective study of 46 patients","volume":"12","author":"Guilhem A","year":"2017","journal-title":"PLoS One"},{"key":"e_1_2_10_43_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2022.104575","article-title":"European Reference Network for Rare Vascular Diseases (VASCERN): when and how to use intravenous bevacizumab in hereditary haemorrhagic telangiectasia (HHT)?","volume":"65","author":"Dupuis\u2010Girod S","year":"2022","journal-title":"Eur J Med Genet"},{"key":"e_1_2_10_44_1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1024\/0301-1526\/a000253","article-title":"Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT)","volume":"42","author":"Chavan A","year":"2013","journal-title":"VASA"},{"key":"e_1_2_10_45_1","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1182\/bloodadvances.2024012589","article-title":"Cost\u2010effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia","volume":"8","author":"Wang D","year":"2024","journal-title":"Blood Adv"},{"key":"e_1_2_10_46_1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.amjoto.2011.07.012","article-title":"Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia","volume":"33","author":"Brinkerhoff BT","year":"2012","journal-title":"Am J Otolaryngol"},{"key":"e_1_2_10_47_1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/lary.20065","article-title":"Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double\u2010blind placebo\u2010controlled clinical trial","volume":"119","author":"Yaniv E","year":"2009","journal-title":"Laryngoscope"},{"key":"e_1_2_10_48_1","first-page":"85","article-title":"The effect of N\u2010acetylcysteine on epistaxis and quality of life in patients with HHT: a pilot study","volume":"47","author":"Gussem EM","year":"2009","journal-title":"Rhinology"},{"key":"e_1_2_10_49_1","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1513\/AnnalsATS.201603-200OC","article-title":"High rates of bleeding complications among hospitalized patients with hereditary hemorrhagic telangiectasia in the United States","volume":"13","author":"Brinjikji W","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"e_1_2_10_50_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.18787\/jr.2025.00009","article-title":"Nasal nitric oxide as an objective evaluation tool for treatment response in chronic rhinitis","volume":"32","author":"Lee S","year":"2025","journal-title":"J Rhinol"},{"key":"e_1_2_10_51_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18787\/jr.2024.00006","article-title":"Efficacy of platelet\u2010rich plasma in the treatment of persistent olfactory impairment after COVID\u201019: a systematic review and meta\u2010analysis","volume":"31","author":"Bae AY","year":"2024","journal-title":"J Rhinol"}],"container-title":["Otolaryngology\u2013Head and Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aao-hnsfjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ohn.70428","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/aao-hnsfjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ohn.70428","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/aao-hnsfjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ohn.70428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:44:41Z","timestamp":1789152281000},"score":1,"resource":{"primary":{"URL":"https:\/\/aao-hnsfjournals.onlinelibrary.wiley.com\/doi\/10.1002\/ohn.70428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":50,"alternative-id":["10.1002\/ohn.70428"],"URL":"https:\/\/doi.org\/10.1002\/ohn.70428","archive":["Portico"],"relation":{},"ISSN":["0194-5998","1097-6817"],"issn-type":[{"value":"0194-5998","type":"print"},{"value":"1097-6817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"2025-11-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ohn.70428"}}